|Articles|June 2, 2023
QualTrak Real-Time PCR and Digital PCR Ecosystem for Streamlined Biologics Development (June 2023)
Author(s)Thermo Fisher Scientific
Biologics—including vaccines, cell and gene therapies, monoclonal antibodies (mAbs), and their biosimilars—have great potential for the treatment and prophylaxis of a broad range of diseases. But, rapid and efficient development of new and effective biologics is no easy feat. With such drastic implications for time and resources, it is imperative that biologic manufacturers choose the right commercial collaborators from the start—agile partners who can improve predictivity, speed, and consistency to bridge basic and clinical research.
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
The FDA Moves to Modernize Drug Manufacturing Registration
2
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
3
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
4
It’s Time to Build a More Scalable, Connected CRO
5